Biotech Values

[pcrutch]

(1) That's only from their experience in the Phase 1/2 study. (2) Tefferi didnt even show up for his poster and Pardanani refused to talk about it. (3) Ruben Mesa basically said that their experience with the drug had none of the issues that the Mayo paper spoke of. He also mentioned that there were a lot of confounding issues in Mayo's Ph1/2 experience; even mentioned that in the Ph1/2 they had particularly sick patients and even noted that a few had lymphoma as well.

that NEJM letter now has zero credibility in my opinion.